ScholarLens Back to search
2001•Journal of Labelled Compounds and RadiopharmaceuticalsRequires access

Precursor synthesis towards the development of [124I]‐labelled 2′, 2′‐difluoro‐2′‐deoxycytidine as a potential pet radiotracer for the anticancer drug gemcitabine

Jennifer A. Wilson, John A. Hadfield, Jake Bailey, Jamal Zweit, Nicholas Thatcher, Roy J. Little

Open publisher page 1 citations

Abstract

Abstract The anticancer nucleoside analogue, Gemcitabine (2′, 2′‐difluoro‐2′‐deoxycytidine) is an active nucleoside against solid tumours. Assessment of tumour and normal tissue concentration of drug in vivo provides pharmacokinetic data that can be related to response to treatment. Towards enabling PET imaging, the synthesis of a halogenated analogue has been undertaken for subsequent radiolabelling with 124I.

About this research paper

What this paper is about

Abstract The anticancer nucleoside analogue, Gemcitabine (2′, 2′‐difluoro‐2′‐deoxycytidine) is an active nucleoside against solid tumours. Assessment of tumour and normal tissue concentration of drug in vivo provides pharmacokinetic data that can be related to response to treatment. Towards enabling PET imaging, the synthesis of a halogenated analogue has been undertaken for subsequent radiolabelling with 124I.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Abstract The anticancer nucleoside analogue, Gemcitabine (2′, 2′‐difluoro‐2′‐deoxycytidine) is an active nucleoside against solid tumours. Assessment of tumour and normal tissue concentration of drug in vivo provides pharmacokinetic data that can be related to response to treatment. Towards enabling PET imaging, the synthesis of a halogenated analogue has been undertaken for subsequent radiolabelling with 124I.

Key concepts: Deoxycytidine, Chemistry, Gemcitabine, Nucleoside analogue, Deoxycytidine kinase, Nucleoside, In vivo, Pharmacokinetics

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Precursor synthesis towards the development of [124I]‐labelled 2′, 2′‐difluoro‐2′‐deoxycytidine as a potential pet radiotracer for the anticancer drug gemcitabine — Research Paper | ScholarLens